It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...
Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...
Pharmaceutical Technology on MSN10d
Biosimilars drive Sandoz growth ahead of unclear tariff effects in 2025Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...
Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...
A Matrix Global Advisors report highlights current barriers and recommendations for robust competition and patient savings in ...
PORTLAND, OR, UNITED STATES, March 11, 2025 /EINPresswire / -- The biosimilar testing and development services market is experiencing rapid growth, projected to surge from $2.5 billion in 2022 to ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...
approved Sandoz’s Enzeevu (aflibercept-abzv), the drugmaker’s biosimilar for wet age-related macular degeneration (AMD), in August 2024. Despite battling for AMD market share against products ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback